Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 84.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 65,805 shares of the company’s stock after acquiring an additional 30,135 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Alto Neuroscience were worth $753,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. bought a new stake in Alto Neuroscience in the first quarter worth about $8,233,000. Jennison Associates LLC increased its stake in Alto Neuroscience by 80.3% in the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after purchasing an additional 370,612 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Alto Neuroscience by 182.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after acquiring an additional 120,779 shares in the last quarter. TD Asset Management Inc purchased a new position in Alto Neuroscience during the 2nd quarter valued at about $928,000. Finally, Bowie Capital Management LLC purchased a new position in Alto Neuroscience during the 2nd quarter valued at about $462,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on ANRO shares. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Robert W. Baird lowered their price target on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus reduced their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $3.81 on Friday. Alto Neuroscience, Inc. has a 12 month low of $3.61 and a 12 month high of $24.00. The stock has a 50 day moving average of $6.49 and a 200-day moving average of $10.07. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. Research analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.